Company: RGBP
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001641172-25-011206
Chunk: 0

Company: Regen BioPharma Inc
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
(Gain) on Investment Securities                                                               -                                                
  Net Cash Provided by (Used in) Operating Activities                                                          ( 66,379                              ( 162,336  
  CASH FLOWS FROM FINANCING ACTIVITIES                                                                                                                          
  Increase (Decrease)in Convertible Notes Payable                                                              65,799                                 ( 46,500  
  Increase (Decrease)in Notes Payable                                                                          -                                                
  Increase ( Decrease) in Common Stock issued for cash                                                                                                 212,297  
  Net Cash Provided by (Used in) Financing Activities                                                          65,799                                  165,797  
  Net Increase (Decrease) in Cash                                                                              ( 581                                     3,460  
  Cash at Beginning of Period                                                                                  716                                     121,037  
  Cash at End of Period                                                                 $                      135            $                        124,497  
  Supplemental Disclosure of Noncash investing and financing activities:                                                                                        
  Preferred Shares Issued for Debt                                                                             -                                                
  Cash Paid for Interest                                                                                       -                                                
  Common shares Issued for Interest                                                                            -                                                
  Preferred Shares issued for Interest                                                                         -                                                

The Accompanying Notes are an Integral Part of These
Financial Statements

   6  

REGEN BIOPHARMA, INC.

Notes to Condensed Consolidated
Financial Statements

As of December 31, 2024

These Notes have been retroactively adjusted to reflect
a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES

The Company was organized April 24, 2012 under the
laws of the State of Nevada

The Company intends to engage primarily in the development
of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase
I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively,
advance the application further to Phase III clinical trials.

The Company is currently engaged in actively identifying
small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression
for autoimmune disease.

The Company is in the early stages of development
of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s
products or therapies. No approval has been granted by the FDA